ライフサイエンスコーパス: breath test

1 outcome measurement using a carbon monoxide breath test).

2 ociated with methane production (measured by breath tests).

3 ltaneous scintigraphy and [13C]octanoic acid breath test.

4 ical fructose-breath test and normal lactose-breath test.

5 gastric emptying was measured via an isotope breath test.

6 investigated by MRI and (13)C-lactose-ureide breath test.

7 Eradication was confirmed with urea breath test.

8 pylori status was confirmed by a (13)C-urea breath test.

9 ding both scintigraphy and C13-octanoic acid breath test.

10 olids was analysed by the [13C]octanoic acid breath test.

11 ylori eradication was determined by 13C-urea breath test.

12 ere screened for H. pylori with the 13C-urea breath test.

13 was assessed by the carbon-13-labelled urea breath test.

14 s were evaluated using the 13C-octanoic acid breath test.

15 cterial overgrowth, the simplest of which is breath tests.

16 of duodenal aspirate, glucose and lactulose breath tests.

17 ireless motility capsules and nonradioactive breath tests.

18 overgrowth (BO) have been evaluated with H2 breath testing.

19 oup C had the highest percentage of negative breath tests (100%), followed by the standard treatment

20 The average breath test (14)CO(2) area under the curves were 1.9- an

21 14C urea breath test (14C-UBT) was performed 4 weeks after the er

22 Cure was determined by using the urea breath test 2 months after antimicrobial treatment.

23 Using breath testing, 26 studies (n = 6700) and 13 studies (n

24 eradication rate, demonstrated by (13)C urea breath test 4 weeks after treatment, analyzed by using t

25 ays and eradication was determined by a urea breath test 4-6 weeks after therapy.

26 Eradication was assessed by urea breath test 6-8 weeks after randomisation.

27 Development of stable-isotope breath tests, allowing in situ phenotype analyses, may e

28 In both groups, a lactose hydrogen breath test and a lactose tolerance test were performed

29 n was found in 22% of patients by means of a breath test and could not be predicted by gastrointestin

30 Lactose hydrogen breath test and lactose tolerance test were positive in

31 re identified based on pathological fructose-breath test and normal lactose-breath test.

32 HP eradication was confirmed using urease breath test and stool antigen test.

33 We assessed GE with a (13)C-spirulina breath test and symptoms in 78 participants with type 1

34 ed with the use of the lactose [(13)C]ureide breath test and the adrenal response to CRF was assessed

35 n CYP3A4 activity using the 14C-erythromycin breath test and the traditional phenotypic trait measure

36 prove eradication rather than just the urea breath test and to use intent-to-treat rather than asses

37 Patients were also tested by a urea breath test and were subjected to esophagogastroduodenos

38 testing evolved from small bowel culture to breath tests and on to next-generation, culture-independ

39 Routine clinical diagnosis relies on breathing tests and visualizing the changes in lung stru

40 g fat), and gastric emptying ((13)C-acetate breath test) and blood glucose, plasma insulin, C-peptid

41 ying was assessed by a labeled octanoic acid breath test, and concentrations of gastrointestinal horm

42 lucose monitors, the 13C-octanoic acid (8:0) breath test, and visual analog scale (VAS) ratings.

43 and plead for caution in the application of breath tests, and those that employ lactulose as the sub

44 or interstitial lung disease, two diagnostic breathing tests, and cigarette smoking history.

45 n breath test (GHBT) using portable hydrogen breath test apparatus (Gastro+(TM) Gastrolyzer by Bedfon

46 Hydrogen (H(2)) and methane (CH(4)) breath tests are a cheap and non-invasive procedure for

47 However, few breath tests are currently used in the clinic to monitor

48 Reported symptoms during breath tests are not a reliable method to diagnose FM/LM

49 We used the 13C urea breath test as the confirmatory method for H. pylori sta

50 Different breath tests assay, (1) exhaled antigen 85, (2) mycobact

51 nd 6 months and with carbon-13-labelled urea breath test at 3 months.

52 tion success was assessed using the 13C-urea breath test at 4-8 weeks post-therapy.

53 verified biochemically using carbon monoxide breath test at 6 months.

54 abstinence verified using a carbon monoxide breath test at 7-month follow-up.

55 abstinence verified using a carbon monoxide breath test at 7-month follow-up.

56 asive techniques, such as breath tests (urea breath test), blood pressure measurements using a sphygm

57 ng diagnostic approaches, reporter phage and breath tests, both of which assay mycobacterial metaboli

58 Consecutive patients who underwent breath testing (BT) from November 2005 to October 2013 w

59 P1A2 activity, the [(13)C 3-methyl] caffeine breath test (CBT), might be clinically useful in identif

60 We tested (13)C-urea breath test-characterized serum samples from 109 U.S. pa

61 hypothesis proves correct, phage assays and breath tests could become important surrogate markers in

62 Increasing breath test "duration" (samples over 4, 5, or 6 hours) y

63 imated using the carbon-14 [14C]erythromycin breath test (ERMBT) before surgery and 24, 48, and 72 hr

64 EXTRAR could potentially spot the (13)C urea breath test false-negatives.

65 easing driver's age and was greater when the breath test for alcohol was positive.

66 rs or older who were interviewed and given a breath test for estimated BAC during roadside surveys th

67 [13C]Octanoic acid breath test for gastric emptying of solids requires furt

68 n the past year) and had a positive C13 urea breath test for H pylori at screening.

69 bitors for 2 weeks before receiving the urea breath test for H. pylori infection.

70 ow the development and evaluation of a rapid breath test for isoniazid (INH)-sensitive TB based on de

71 l-gas biopsies and noninvasive mixed-exhaled-breath testing for esophagogastric-cancer detection.

72 2012, and Nov 22, 2017, 30 166 patients had breath testing for H pylori, 5367 had a positive result,

73 ergic, cardiovagal, and sudomotor subscores, breath testing for small intestinal bacterial overgrowth

74 covered include improving the specificity of breath tests for bacterial overgrowth; small bowel enter

75 We did not evaluate breath tests for small intestinal bacterial overgrowth,

76 The advent and ready availability of breath tests generated a dramatic expansion in both the

77 (by Echosens, France), and glucose hydrogen breath test (GHBT) using portable hydrogen breath test a

78 They underwent a 14C-urea breath test, H. pylori serology, fasting gastrin, gastri

79 Thus, breath test half emptying time (t1/2) minus 66 minutes w

80 A noninvasive breath test has the potential to improve survival from e

81 However, adoption of breath testing has been limited by a lack of standardiza

82 electrogastrography, and the C octanoid acid breath test have been used in the study of normal and ab

83 r, issues with the specificity of these same breath tests have clouded their interpretation and arous

84 Both reporter phage and breath tests have promise as early markers to determine

85 underwent a 25 g lactose challenge hydrogen breath test (HBT) before and after the 12-wk interventio

86 levels of H2 and CH4 in a positive hydrogen breath test (HBT) was demonstrated.

87 in the same patients with IBS using hydrogen breath testing (HBT).

88 nd clinical symptoms were compared with H(2) breath tests (HBT) for FM/LM.

89 All patients underwent H<inf>2</inf> Breath-Test (HBT) and two questionnaires regarding the s

90 eted gas, a prevalence of abnormal lactulose breath test in 84% of IBS patients, and a 75% improvemen

91 easured with the [14C N-methyl] erythromycin breath test in each subject.

92 ate the accuracy and reproducibility of this breath test in healthy subjects.

93 cin (a Pgp substrate) using the erythromycin breath test in mice proficient and deficient of mdr1 dru

94 ion rate of H pylori, assessed by (13)C urea breath test, in both intention-to-treat and per-protocol

95 ]fatty acids, exogenous lipid oxidation with breath-test/indirect calorimetry, and fecal excretion.

96 Methane (CH4) breath test is an established diagnostic method for gast

97 tility and specificity of lactulose hydrogen breath testing is yet again being called into question.

98 tility and specificity of lactulose hydrogen breath testing is yet again questioned and further data

99 ed screening tests such as liquid biopsy and breathing tests may transform the screening landscape.

100 The (13) C-methacetin breath test (MBT) is a noninvasive, quantitative hepatic

101 earance (Cl), MEGX concentration, methionine breath test (MBT), galactose elimination capacity (GEC),

102 enylacetate), 1 prognostic [ 13 C-methacetin breath test (MBT)], and 1 mechanistic (rotational thromb

103 CH(4) breath tests (MBT), blood sugar tests (BST) and clinical

104 The liver maximum capacity (LiMAx) breath test measures enzymatic liver function and could

105 ot suitably enforced-for example with random breath testing measures.

106 re assessed based on symptom improvement and breath test normalization.

107 regimens leading to symptom improvement and breath test normalization.

108 timized and validated a stable isotope-based breath test of intestinal sucrase activity ((13)C-SBT) a

109 Follow-up 14C-urea breath tests of all 102 patients who eradicated H. pylor

110 a GLP-1 concentrations and gastric emptying (breath test) over 240 min.

111 While breath tests reflected the mucosa-associated bacterial c

112 Newer imaging methods and breath tests require further validation, but appear prom

113 H. pylori was not eradicated had a negative breath test result while receiving lansoprazole.

114 The proportions of patients whose breath test results were positive after completion of la

115 was associated with IBS symptom severity and breath tests results at baseline (H(2) and/or CH(4) >= 1

116 Consecutively 13C urea breath tests results were extracted from the files over

117 ues were observed in some subjects, repeated breath tests showed a high degree of reproducibility wit

118 Eradication was assessed by urea breath test six weeks after treatment completion.

119 Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth (S

120 al or moderate test methods (scintigraphy or breath test, solid meal, >2 hours duration) compared to

121 All participants had (13)C-spirulina GE breath test T1/2 values of 79 minutes or more (with 89.8

122 gh non-invasive [(13)C]-propionate oxidation breath test to derive functional cut-off and tested its

123 utine addition of H pylori screening by urea breath test to standard care in all patients hospitalize

124 Mice were given breath tests to analyze GE of solids.

125 Using these nanosensors, we performed serial breath tests to monitor dynamic changes in neutrophil el

126 Participants with a positive (13)C-urea breath test (UBT) 6 to 8 weeks posttreatment were offere

127 H. pylori colonization by using the 13C-urea breath test (UBT) and were asked to provide fecal sample

128 The 13C urea breath test (UBT) has been shown to be an extremely accu

129 pose of this study was to use the (13)C Urea Breath Test (UBT) in measuring the effectiveness of seco

130 pper endoscopy with histology, RUT, and urea breath test (UBT).

131 cluded 154 patients with positive (13)C-urea breath test (UBT).

132 of H. pylori infection by serology and urea breath test (UBT).

133 Noninvasive techniques, such as breath tests (urea breath test), blood pressure measurem

134 Previous work suggested that a breath test using 13C accurately measures gastric emptyi

135 < 150, underwent a gastric emptying test by breath test using 13C octanoic acid coupled to a solid m

136 Carbon labeled urea breath tests usually entail a two point sampling with a

137 The erythromycin breath test was evaluated to determine hepatic activity

138 The erythromycin breath test was next administered to mdr1a(-/-) and mdr1

139 The urea breath test was repeated at 28 days.

140 The breath test was repeated three times within a 3-week per

141 The erythromycin breath test was used to measure CYP3A4 activity in vivo

142 ri prevalence, as determined by the 13C-urea breath test, was 69%, and prevalence increased from 53%

143 Patients referred to fructose breath test were further selected to identify those havi

144 Parameters from scintigraphy and breath test were not correlated significantly.

145 stological assessment, rapid urease test and breath test were performed before and eight weeks after

146 s who tested positive for H pylori by a urea breath test were randomly assigned by a central computer

147 alprotectin, thyroid tests, celiac serology, breath tests were more frequently suggested in IBS-C and

148 diagnosed on the basis of (13)C-labeled urea breath tests) were enrolled in a household-randomized, u

149 y, all patients underwent a gastric emptying breath test with assessment of postprandial severity of